Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

1.390 +0.060 (+4.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Peering Into Editas Medicine's Recent Short Interest
Via Benzinga
Editas Medicine Announces Chief Financial Officer Transition
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027. 
Via Stocktwits
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
From Editas Medicine, Inc.
Via GlobeNewswire
12 Analysts Have This To Say About Editas Medicine
Via Benzinga
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts
Via Benzinga
Earnings Scheduled For March 5, 2025
Via Benzinga
What's going on in today's session
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Top movers in Thursday's session
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Top movers analysis one hour before the close of the markets on 2025-02-19: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
Here are the top movers in Wednesday's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution
Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines. 
Via Benzinga
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
Editas Medicine pivots to in vivo gene editing, extends cash runway to Q2 2027, and reduces its workforce by 65%. The company reports breakthroughs in HSC and liver editing. 
Via Benzinga
Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30
Via Talk Markets
Topics Stocks / Equities
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13. 
Via Benzinga
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
From Editas Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.